MDxHealth Announces Preliminary Third Quarter 2026 Revenue and Suspends Full-Year 2026 Revenue Guidance
Key Highlights
- ➤Q3 revenue approximately $22.7 million, flat versus the re-presented prior-year period
- ➤Full-year 2026 revenue guidance of $110–115 million suspended
- ➤Tissue-based test volume 11,232, down 11% year over year
- ➤Liquid-based test volume 11,792 versus 4,600 in the prior-year period
- ➤Cash and cash equivalents approximately $31.7 million at September 30, 2026
Expert Statements
Michael K. McGarrity, CEO of mdxhealth
“Third quarter revenue fell short of our expectations. Following the discontinuation of Resolve mdx, we experienced unexpected turnover within our sales force catalyzed by aggressive targeting from recruiters. While we have a disciplined process which has served as the foundation of our forecast accuracy over the past three years, that process was clearly disrupted by this recent impact on our sales force.”
Michael K. McGarrity, CEO of mdxhealth
“Although this led to an interruption in the progress we reported in Q2, we are focused on fortifying impacted territories and returning to consistent execution. Importantly, we do not believe these factors represent a change in the reputation that we have built with our customer base, the underlying clinical demand for our products, or our long-term market opportunity, and we expect to return to growth within these end markets. We will provide additional detail on our corrective actions and progress when we report our full third quarter results and host our earnings call on November 12.”
IRVINE, CA – October 15, 2026 (GlobeNewswire) – MDxHealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced preliminary unaudited revenue from continuing operations for the third quarter ended September 30, 2026, and suspends its full-year 2026 revenue guidance of $110–115 million.
The Company expects to report third quarter 2026 revenue from continuing operations of approximately $22.7 million, compared to $22.7 million in the third quarter of 2025 (re-presented to exclude Resolve mdx, which is reported as a discontinued operation). Third quarter tissue-based (Confirm mdx and GPS mdx) test volume was 11,232, a decrease of 11% from the prior-year period. Third quarter liquid-based (Exo mdx) test volume was 11,792 compared to 4,600 in the prior-year period, which included Select mdx and Exo mdx from its September 2025 acquisition. Cash and cash equivalents were approximately $31.7 million as of September 30, 2026.
Get started
Create a free account to read the full story.